{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"14.0","upperLimit":"36.5","value":"23.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"Whether or not the patient survived progression-free for at least 6 months.","dispersionType":"90% Confidence Interval","groups":[{"description":"Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy","id":"OG000","title":"Bevacizumab"}],"paramType":"NUMBER","populationDescription":"Eligible and Treated Patients","reportingStatus":"POSTED","timeFrame":"Every other 3-week treatment cycle for 6 months","title":"Progression-free Survival Greater Than 6 Months","type":"PRIMARY","unitOfMeasure":"percentage of participants"}